OrthoPediatrics (NASDAQ:KIDS) Trading Down 6.2% – What’s Next?

OrthoPediatrics Corp. (NASDAQ:KIDS)’s stock price traded down 6.2% during mid-day trading on Tuesday . The stock traded as low as $18.61 and last traded at $19.4410. 24,101 shares were traded during trading, a decline of 85% from the average session volume of 157,850 shares. The stock had previously closed at $20.72.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on KIDS. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. BTIG Research restated a “buy” rating and issued a $24.00 price objective on shares of OrthoPediatrics in a report on Friday, May 1st. Canaccord Genuity Group set a $25.00 price objective on shares of OrthoPediatrics in a research report on Friday, April 24th. Weiss Ratings reiterated a “sell (e+)” rating on shares of OrthoPediatrics in a research note on Tuesday, April 21st. Finally, Truist Financial set a $17.00 target price on shares of OrthoPediatrics in a research report on Friday, May 1st. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $24.44.

OrthoPediatrics Price Performance

The stock’s 50-day moving average price is $18.57 and its 200 day moving average price is $17.67. The firm has a market cap of $506.41 million, a price-to-earnings ratio of -11.74 and a beta of 0.99. The company has a quick ratio of 2.37, a current ratio of 5.21 and a debt-to-equity ratio of 0.29.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Thursday, April 30th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.04. The business had revenue of $59.36 million for the quarter, compared to the consensus estimate of $58.28 million. OrthoPediatrics had a negative return on equity of 7.01% and a negative net margin of 16.31%. Equities research analysts predict that OrthoPediatrics Corp. will post -1.13 earnings per share for the current year.

Institutional Trading of OrthoPediatrics

Institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its position in OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after purchasing an additional 1,139 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after buying an additional 2,561 shares during the period. Caption Management LLC acquired a new position in shares of OrthoPediatrics in the 3rd quarter valued at $54,000. BNP Paribas Financial Markets lifted its holdings in shares of OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after acquiring an additional 1,235 shares during the period. Finally, State of Wyoming boosted its position in shares of OrthoPediatrics by 189.7% during the 4th quarter. State of Wyoming now owns 6,822 shares of the company’s stock valued at $121,000 after acquiring an additional 4,467 shares in the last quarter. 69.05% of the stock is currently owned by institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.